Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phendione, also known as phanquinone, is a small molecule phenanthroline derivative that historically served as an amoebicide and antibacterial agent. Recent research has identified it as a potent agonist of the bitter taste receptor T2R5 (TAS2R5). In the context of oncology, specifically head and neck squamous cell carcinoma (HNSCC), phendione activates endogenously expressed T2R5, triggering sustained intracellular calcium responses that lead to reduced cell viability and the induction of apoptosis. This mechanism suggests a potential tumor-suppressive role for T2R5 in HNSCC. Beyond its role as a T2R5 agonist, phendione is a known metal chelator, which contributes to its broad-spectrum antimicrobial activity against various pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phendione.